Dr. Michael J. Kelley
Claim this profileDurham VA Medical Center
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
9 reported clinical trials
18 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage III
Stage II
2Non-Small Cell Lung Cancer
Stage IV
Stage III
PD-L1 positive
Affiliated Hospitals
Clinical Trials Michael J. Kelley is currently running
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
More about Michael J. Kelley
Clinical Trial Related6 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Michael J. Kelley has experience with
- Pembrolizumab
- Pemetrexed
- Carboplatin
- Itraconazole
- Talazoparib
- Avelumab
Breakdown of trials Michael J. Kelley has run
Lung Cancer
Non-Small Cell Lung Cancer
Esophageal Carcinoma
Esophageal Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael J. Kelley specialize in?
Michael J. Kelley focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Michael J. Kelley currently recruiting for clinical trials?
Yes, Michael J. Kelley is currently recruiting for 3 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Michael J. Kelley has studied deeply?
Yes, Michael J. Kelley has studied treatments such as Pembrolizumab, Pemetrexed, Carboplatin.
What is the best way to schedule an appointment with Michael J. Kelley?
Apply for one of the trials that Michael J. Kelley is conducting.
What is the office address of Michael J. Kelley?
The office of Michael J. Kelley is located at: Durham VA Medical Center, Durham, North Carolina 27705 United States. This is the address for their practice at the Durham VA Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.